ASCO GU 2018: Progression after IO combination regimens mRCC

February 21, 2018

  • Share this post:

Pedro Barata, experimental therapeutics clinical fellow at the Taussig Cancer Institute Cleveland Clinic, explains the design and results of the trial he presented during the poster session. This retrospective study examined the clinical outcome of patients with metastatic renal cell carcinoma progressing on frontline immune-oncology based combination regimens.

Our ASCO GU coverage is editorially independent and financially made possible by Bayer and Janssen.

Related articles